跳至主要内容
临床试验/NCT00139555
NCT00139555已完成4 期

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Novartis1 个研究点 分布在 1 个国家目标入组 125 人开始时间: 2004年7月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
125
试验地点
1
主要终点
Change from baseline in left ventricular mass index after 52 weeks

研究概览

简要总结

Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
55 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Males or female patients ≥ 55 years of age
  • •LVH as confirmed by echocardiogram
  • •Patients with high risk hypertension, currently treated or already taking antihypertensive medication

排除标准

  • •Renal artery stenosis
  • •Symptomatic heart failure or known ejection fraction < 40%
  • •Myocardial infarction or stroke within 6 months
  • •Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers
  • •Pregnant or lactating females
  • •Cancer within the last 5 years

结局指标

主要结局

Change from baseline in left ventricular mass index after 52 weeks

次要结局

  • Change from baseline in aorta function assessed blood pressure measurements after 52 weeks
  • Change from baseline in left ventricular mass after 52 weeks
  • Change from baseline in diastolic function after 52 weeks
  • Change from baseline in markers of fibrosis and increased heart size after 52 weeks

研究者

发起方
Novartis
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Effects of Amlodipine/Benazepril in Reducing Left... | 临床试验